TI 061

Drug Profile

TI 061

Alternative Names: TI-061

Latest Information Update: 13 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tioma Therapeutics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD47 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 13 Oct 2017 Tioma Therapeutics terminates a phase I/II trial in Solid tumours (Late-stage disease, Monotherapy, Combination therapy, In adults, In the elderly) in United Kingdom (EudraCT2016-004372-22)
  • 16 Jun 2017 Tioma Therapeutics has intellectual property rights for anti-CD47 antibodies
  • 02 Jun 2017 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Combination therapy, In adults, In the elderly) in United Kingdom (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top